All Clinical Trials
Below is a list of all clinical trials, conducted by several of our specialty service lines. You may filter the list of trials by clicking the "Department" dropdown menu and selecting the area that you want to view or that pertains to you.
Clicking "Learn More" may either take you to more information about our departments that conduct the research, or to the official clinicaltrials.gov page for more information about the trial.
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)”
A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Back Pain (RESET)
Study # NCT04246281 Date Opened: 06/17/2020 Closing Date: 03/31/2026 Sponsor: SPR Therapeutics
ThromboelAstogRaphy Guided Approach to Reduce Recurrent Events in ACS Patients Undergoing Catheter Based Intervention (TARGET-ACS)
Study # TARGET-ACS
Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
Study # FcGammaRIIa
A Single-Dose, Open-Label, Randomized, Multi-Center, 2-Treatment Crossover Study To Compare The Pharmacodynamics, Pharmacokinetics, Safety, And Tolerability Of Acetylsalicylic Acid Powder For Oral Inhalation With Non-Enteric-Coated Chewable Aspirin In Adu
Study # NCT05625347
Multidisciplinary Approach to Reduce Cardiovascular Health Disparities in the Baltimore Racial Minority Communities (M-BRACE Trial)
Study # M-BRACE Trial
A Study of the ReCor Medical Paradise System in Clinical Hypertension
Study # NCT02649426
A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy parallel-group, 2-arm, Phase 3 study to compare the efficacy of the oral FXIa inhibitor asundexian with apixaban for the prevention of stroke or systemic em
Study # SCFTR-02
A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)
Study # VICTORION-2 PREVENT
Randomized Phase 3 Clinical Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) (NCT#3851445)
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
Study # APAL2020SC Date Opened: 04/18/2022
A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations AAML1831
Study # AAML1831 Date Opened: 07/21/2020
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Study # AAML18P1 Date Opened: 11/08/2019
Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Study # ADVL1823 Date Opened: 10/25/2019
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Study # AALL1732 Date Opened: 10/31/2019
A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl
Study # AALL1731 Date Opened: 07/03/2019
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
Study # AALL1631 Date Opened: 08/08/2017
